Mouse arcuate nucleus — cagrilintide response (bulk RNA-seq)
Mus musculus · Arcuate nucleus · bulk RNA-seq
Selected data and study scope
This dataset contains bulk RNA-seq data from Mus musculus, sampled from arcuate nucleus. The default comparison examines gene expression in AM833 / cagrilintide relative to Vehicle.
The explorer includes 1 track and 1 comparison for this dataset.
The default track, Arcuate nucleus (ARC), includes 7 Vehicle samples and 8 AM833 / cagrilintide samples in this comparison. These are analysis sample counts. Check the source for biological replication and pooling.
Interpretation and limitations
The measurement combines expression from the cells in the tissue sample. A difference in tissue expression alone does not identify which cell type contributes to it.
Expression values use log2(gene-summed TPM + 1). Keep this unit when exporting or comparing values. Values on other normalization scales are not directly interchangeable.
Evidence and verification
Pipeline QC passed. Mouse arcuate nucleus — cagrilintide response (bulk RNA-seq); all 1 registered contrasts on default track arcuate
Experimental design passed. Mouse arcuate nucleus — cagrilintide response (bulk RNA-seq); all 1 registered contrasts on default track arcuate
Author concordance not assessed. Author effect concordance has not been assessed
Pipeline QC can pass while experimental-design limitations remain. Read both assessments before interpreting results.
Open the dataset in the Explorer to read each check and its evidence. Author concordance compares effects for matched genes. It does not require identical author P values or FDR.
Read the analysis methods and interpretation guide and how to cite the source study and HypoExplorer. The source publication may include tissues, groups or comparisons beyond the data shown here.
Source study
Wild-type 129/Sv-mouse arcuate nucleus, seven deposited vehicle vs eight deposited AM833/cagrilintide-treated animals; knockout, salmon-calcitonin, area-postrema and LPBN arms are excluded. The series and paper resolve the RNA-seq dose as 3 nmol/kg, while individual sample records retain stale 0.3 nmol/kg labels. The paper reports six replicates per condition and only two unidentified CountQC ARC exclusions, which cannot reconcile 15 deposits with its 12-sample cohort; this therefore remains an all-deposited-sample analysis rather than the exact author cohort (PMID 40609154; GSE296488)
Source publication
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.
Carvas AO, Leuthardt A, Kulka P, Lommi G, Hassan S, Coester B, et al.
EBioMedicine · 2025
Repository study title
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3
The original study authors produced these data. HypoExplorer displays selected data and analyses that may cover only part of the study.
Comparisons in HypoExplorer
AM833 / cagrilintide vs Vehicle · default
Positive differential-expression values indicate higher expression in the case group relative to the baseline. Check the comparison direction and study design when interpreting results.
Available tracks
| Track | Features | Vehicle n | AM833 / cagrilintide n |
|---|---|---|---|
| Arcuate nucleus (ARC) | 28,705 | 7 | 8 |
Expression and analysis results
Open this dataset to inspect gene expression and differential-expression results across the available tracks. Pathway enrichment is also available. The pathway databases differ by dataset.
HypoExplorer is in beta testing. Features and analyses may change during testing. Review the original source, analysis methods and quality-control checks before using a result in research.